Quick Answer
Vor Biopharma Inc. reported Cash and Equivalents of $396.49 million for fiscal year 2025.
Vor Biopharma Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $396.49M | +383.8% |
| 2024 | $81.95M | +161.3% |
| 2023 | $31.36M | -45.7% |
| 2022 | $57.71M | -51.8% |
| 2021 | $119.80M | +146.8% |
| 2020 | $48.54M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $160.46M | +203.9% | -15.8% |
| June 30, 2025 | $190.57M | +150.5% | +280.8% |
| March 31, 2025 | $50.05M | +11.3% | -38.9% |
| December 31, 2024 | $81.95M | +161.3% | +55.2% |
| September 30, 2024 | $52.80M | +17.3% | -30.6% |
| June 30, 2024 | $76.08M | +136.2% | +69.2% |
| March 31, 2024 | $44.96M | +5.9% | +43.4% |
| December 31, 2023 | $31.36M | -45.7% | -30.4% |
- Vor Biopharma Inc. showed an increase of +383.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Vor Biopharma Inc.’s cash and equivalents has grown by 716.8% (from $48.54 million to $396.49 million).
- The most recent figure is from Vor Biopharma Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: